Frequently Asked Questions
Financial/Shareholder Information
Q:
On which exchange is Repligen traded, and what is the ticker?
A:
Repligen is traded on the NASDAQ under the ticker RGEN.
Q:
In what year did Repligen go public?
A:
Repligen began trading on the NASDAQ May 6, 1986 under the ticker RGEN.
Q:
Who do I contact if I’ve lost stock certificates, moved or would like to transfer my certificates to another person?
A:
If you hold your shares in a brokerage account, please contact your broker.
If you hold your stock certificates directly, please contact our transfer agent, American Stock Transfer & Trust Company with your question or to provide your new contact information.
American Stock Transfer & Trust Company
59 Maiden Lane
Plaza Level
New York, NY 10038
Phone: 877.777.0800, select option 1
Web: http://www.amstock.com
Q:
Can I purchase stock directly from Repligen?
A:
No, Repligen does not have a direct purchase program. You must purchase stock through a broker.
Q:
What is Repligen’s policy on dividends?
A:
Repligen has never paid any cash dividends on our common stock and does not anticipate paying cash dividends in the foreseeable future. Repligen is building value for shareholders through reinvestment in our development pipeline.
Q:
What is Repligen’s fiscal calendar?
A:
Our fiscal year ends on March 31 of each calendar year.
Q:
How many Repligen shares are outstanding?
A:
As of December 31, 2010 there were approximately 30.7 million shares outstanding (32.8 million, including options)
Q:
How much cash does Repligen have?
A:
Cash and marketable securities as of December 31, 2010 were $60.3 million, excluding restricted cash.
Q:
What is Repligen’s average burn rate?
A:
Repligen has estimated for fiscal year 2011, ending March 31, 2011 $0.5M to $1.5M in cash flow generation.
Q:
Who are Repligen’s independent auditors?
A:
Ernst & Young, LLP.
Corporate Information
Q:
When and where was Repligen incorporated?
A:
Repligen was incorporated in May 1981 in Delaware.
Q:
Where are Repligen’s corporate headquarters?
A:
Repligen’s principle executive offices are at 41 Seyon Street, Waltham, Massachusetts 02453.
Q:
How many employees does Repligen have?
A:
As of March 31, 2011, Repligen had 76 employees.
Q:
How many clinical trials is Repligen conducting?
A:
Please see our Product page for more information about our development pipeline.
Q:
Does Repligen have any products on the market?
A:
Yes. Repligen currently markets a line of products based on Protein A, which are used by pharmaceutical companies in the production of monoclonal antibodies.